Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GCK | P35557 | 7/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15282745 | 0.91 | ADORA1 (0.44) | ADORA1GRAMD1AMAPTKDM4EGCK | |
| SCHEMBL165650 | 0.84 | GRAMD1A (0.53) | ADORA1GRAMD1AMAPTKDM4EGCK | |
| SCHEMBL12761195 | 0.84 | GRAMD1A (0.53) | ADORA1GRAMD1AMAPTKDM4EGCK | |
| SCHEMBL17993838 | 0.84 | GRAMD1A (0.53) | ADORA1GRAMD1AMAPTKDM4EGCK | |
| SCHEMBL172106 | 0.83 | ADORA1 (0.56) | ADORA1GRAMD1AMAPTKDM4EGCK | |
| SCHEMBL2699291 | 0.83 | GRAMD1A (0.53) | ADORA1GRAMD1AMAPTKDM4EGCK | |
| SCHEMBL12234755 | 0.83 | GRAMD1A (0.53) | ADORA1GRAMD1AMAPTKDM4EGCK | |
| SCHEMBL3441645 | 0.82 | GRAMD1A (0.52) | ADORA1GRAMD1AMAPTKDM4EGCK | |
| SCHEMBL741444 | 0.82 | ADORA1 (0.55) | ADORA1GRAMD1AMAPTKDM4EGCK | |
| SCHEMBL210375 | 0.81 | ADORA1 (0.54) | ADORA1GRAMD1AMAPTKDM4EGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | ADORA1 1327/4885GRAMD1A 1172/4885MAPT 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.